Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 3, 2010, Pages 463-471

  Olivieri, O ^a   Martinelli, N ^a   Girelli, D ^a   Pizzolo, F ^a   Friso, S ^a   Beltrame, F ^b   Lotto, V ^a   Annarumma, L ^a   Corrocher, R ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Institute of Cardiology   (Italy)

Author keywords

Apolipoprotein C III; Coronary artery disease; Secondary prevention; Thrombin generation; Triglycerides

Indexed keywords

APOLIPOPROTEIN C3; C REACTIVE PROTEIN; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THROMBIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SECONDARY PREVENTION;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; APOLIPOPROTEIN C-III; BIOLOGICAL MARKERS; BLOOD COAGULATION TESTS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; THROMBIN; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 77949291008     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03720.x     Document Type: Article

References (41)

1. Smith SC, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert KA. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001, 104:1577-9.
2. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113:2363-72.
3. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115:450-8.
4. Jong MC, Hofker MH, Havekes LM. Role of apo Cs in lipoprotein metabolism. Functional differences between apoC1, apoC2, and apo C3. Arterioscler Thromb Vasc Biol 1999, 19:472-84.
5. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum N, Brown WV. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII. Evidence AI that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986, 78:1287-95.
6. McConathy WJ, Gesquiere HB, Tartar A, Fruchart JC, Wang CS. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 1992, 33:995-1003.
7. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 2006, 113:691-700.
8. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006, 114:681-7.
9. Kawakami A, Osaka M, Tani M, Azuma H, Sacks FM, Shimokado K, Yoshida M. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 2008, 118:731-42.
10. Bobik A. Apolipoprotein CIII and atherosclerosis. Beyond effects on lipid metabolism. Circulation 2008, 118:702-4.
11. Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003, 23:853-8.
12. Onat A, Hergenc G, Sansoy V, Fobker M, Ceyhan K, Toprak S, Assmann G. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 2003, 168:81-9.
13. Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, Girelli D, Friso S, Pignatti PF, Corrocher R. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res 2003, 44:2374-81.
14. Luc G, Fievet C, Arveiler D, Evans AE, Bard JM, Cambien F, Fruchart JC, Ducimetiere P. Apolipoproteins C-III and E in apo B- and non-apo B-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. J Lipid Res 1996, 37:508-17.
15. Gerber Y, Goldbourt U, Segev S, Harats D. Indices related to apo CII and CIII serum concentrations and coronary heart disease: a case-control study. Prev Med 2003, 37:18-22.
16. Olivieri O, Stranieri C, Bassi A, Zaia B, Girelli D, Pizzolo F, Trabetti E, Cheng S, Grow MA, Pignatti PF, Corrocher R. ApoC-III gene polymorphisms and risk of coronary artery disease. J Lipid Res 2002, 43:1450-7.
17. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation 1990, 81:470-6.
18. Alaupovic P, Hodis HN, Knight-Gibson C, Mack WJ, LaBree L, Cashin-Hemphill L, Corder CN, Kramsch DM, Blankenhorn DH. Effects of lovastatin on ApoA-, ApoB-containing lipoproteins. Families in a subpopulation of patients participating in the Regression Monitored Atherosclerosis Study (MARS). Arterioscler Thromb 1994, 14:1906-13.
19. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000, 102:1886-92.
20. Hemker CH, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006, 96:553-61.
21. Calatzis A, Reininger AJ, Spannagl A, Schramm W. Rapid and automated quantification of the kinetics of thrombin formation using the Thrombin Dynamics Test (TDT). J Thromb Haemost 2003, 1(Suppl. 1):P1589.
22. Nagelkerke N. A note on a general definition of the coefficient of determination. Biometrika 1991, 78:691-2.
23. Chan DC, Watts GF, Barett PH, Mamo JCL, Redgrave TG. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem 2002, 48:278-83.
24. Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, Girelli D, Friso S, Pignatti PF, Corrocher R. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res 2003, 44:2374-81.
25. Attman PO, Samuelsson O. Dyslipidemia of kidney disease. Curr Opin Lipidol 2009, 20:293-9.
26. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-9.
27. Scheffer PG, Teerlink T, Dekker JM, Bos G, Nijpels G, Diamant M, Kostense PJ, Stehouwer CD, Heine RJ. Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study. Clin Chem 2008, 54:1325-30.
28. Atzmon G, Rincon M, Schechter CB, Shuldiner AR, Lipton RB, Bergman A, Barzilai N. Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol 2006, 4:e113.
29. Kawakami A, Yoshida M. Apolipoprotein CIII links dyslipidemia with atherosclerosis. J. Atheroscler Thromb 2009, 16:6-11.
30. Chan DC, Chen MM, Ooi EM, Watts GF. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? Int J Clin Pract 2008, 62:799-809.
31. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation 1990, 81:470-6.
32. Hodis HN, Mack WJ, Azen SP, Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994, 90:42-9.
33. Rota S, McWilliam NA, Baglin TP, Byrne CD. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood 1998, 91:508-15.
34. Kawakami A, Osaka M, Aikawa M, Uematsu S, Akira S, Libby P, Shimokado K, Sacks FM, Yoshida M. Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res 2008, 103:1402-9.
35. Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. Semin Thromb Hemost 2006, 32:32-8.
36. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108:1664-72.
37. Brummel-Ziedins K, Undas A, Orfeo T, Gissel M, Butenas S, Zmudka K, Mann KG. Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J Thromb Haemost. 2008, 6:104-10.
38. Orbe J, Zudaire M, Serrano R, Coma-Canella I, Martínez de Sizarrondo S, Rodríguez JA, Páramo JA. Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. Thromb Haemost 2008, 99:382-7.
39. Martinelli N, Trabetti E, Pinotti M, Olivieri O, Sandri M, Friso S, Pizzolo F, Bozzini C, Caruso PP, Cavallari U, Cheng S, Pignatti PF, Bernardi F, Corrocher R, Girelli D. Combined effect of hemostatic gene polymorphisms and the risk of myocardial infarction in patients with advanced coronary atherosclerosis. PLoS ONE 2008, 3:e1523.
40. Olin-Lewis K, Krauss RM, La Belle M, Blanche PJ, Barrett PH, Wight TN, Chait A. ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. J Lipid Res 2002, 43:1969-77.
41. Griffin JH, Fernandez JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 2001, 86:386-94.